In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

Organon said that as a result of the delay, it now expects Vtama to contribute about $125 million in revenue next year, with the Dermavant deal reducing its 2025 adjusted earnings before interest ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

statements about management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval from the FDA for the use of ...

Appleby Bermuda advised Organon & Co on the acquisition, by way of merger under Bermuda law, of Dermavant Sciences Ltd. Organon (NYSE: OGN) is a global healthcare company with a mission to improve the ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. The AI ...

Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part Organon is paying $175 million upfront to buy Roivant's dermatology unit ...

Organon (NYSE:OGN) projected a roughly 75 basis-point headwind to the company’s 2025 EBITDA margin on Tuesday after the FDA delayed a potential label expansion for its skin disorder therapy ...

Organon & Co. (NYSE:OGN) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to US$16.92 in the week after its latest quarterly results. Results were roughly in ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.